Sugi Predict

Sugi Predict / Compounds / SCHEMBL2911096

SCHEMBL2911096

SCHEMBL2911096

NC(=O)CCN1CCSCC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ ARG1 P05089 1/20 0.41
▸ ARG2 P78540 1/20 0.41
▸ MAPT P10636 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ GLA P06280 1/20 0.35
▸ HTT P42858 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ KEAP1 Q14145 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ CA2 P00918 2/20 0.33
▸ KDM1A O60341 2/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29973401 0.89 L3MBTL1 (0.50) L3MBTL1ARG1ARG2MAPTPOLB
SCHEMBL2361330 0.88 L3MBTL1 (0.53) L3MBTL1ARG1ARG2MAPTPOLB
SCHEMBL30701355 0.86 L3MBTL1 (0.47) L3MBTL1ARG1ARG2MAPTALDH1A1
SCHEMBL11598668 0.84 L3MBTL1 (0.77) L3MBTL1MAPTPOLBALDH1A1SMN1; SMN2
SCHEMBL8860545 0.84 L3MBTL1 (0.77) L3MBTL1MAPTPOLBALDH1A1SMN1; SMN2
SCHEMBL3366792 0.80 L3MBTL1 (0.41) L3MBTL1ARG1ARG2MAPTPOLB
SCHEMBL4381054 0.80 GLA (0.55) L3MBTL1ARG1ARG2MAPTPOLB
SCHEMBL1007439 0.79 L3MBTL1 (0.95) L3MBTL1MAPTPOLBALDH1A1SMN1; SMN2
SCHEMBL14621962 0.78 PAOX (0.46) L3MBTL1ARG1ARG2MAPTPOLB
SCHEMBL2106140 0.77 KDM4E (0.56) L3MBTL1ARG1ARG2MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182308-B1 PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS CHIESI FARM SPA (IT) 2024-09-04 — — EP claimed
CN-115160193-B Naphthalene sulfonamide micromolecule compound and application thereof 中国人民解放军海军军医大学 2023-09-15 — — CN disclosed
CN-116096719-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2023-05-09 — — CN disclosed
CN-115160193-A Naphthalene sulfonamide micromolecule compound and application thereof 中国人民解放军海军军医大学 2022-10-11 — — CN disclosed
US-20160243102-A1 RHO KINASE INHIBITORS ALCON INC. (CH) 2016-08-25 — — US disclosed
US-20150297581-A1 RHO KINASE INHIBITORS ALCON INC. (CH) 2015-10-22 — — US disclosed
US-20140357652-A1 RHO KINASE INHIBITORS ALCON INC. (CH) 2014-12-04 — — US disclosed
US-8809326-B2 Isoquinolinone Rho kinase inhibitors AERIE PHARMACEUTICALS, INC. (US) 2014-08-19 — — US disclosed
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 — — EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 — — US disclosed
US-20080161297-A1 e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, ALCON INC. (CH) 2008-07-03 — — US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 — — US disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 — — EP disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 — — US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
CN-1759110-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2006-04-12 — — CN disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 — — EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 L3MBTL1 4635/4885ARG1 759/4885ARG2 257/4885
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 L3MBTL1 3613/4885ARG1 346/4885ARG2 220/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 L3MBTL1 4745/4885ARG1 1417/4885ARG2 995/4885
US-20160243102-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, CIT L3MBTL1 3493/4885ARG1 1325/4885ARG2 867/4885
US-20150297581-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, CIT L3MBTL1 3493/4885ARG1 1325/4885ARG2 867/4885
US-20140357652-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, CIT L3MBTL1 3493/4885ARG1 1325/4885ARG2 867/4885
US-20080161297-A1 e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, ROCK1, ROCK2, ARHGDIA L3MBTL1 3539/4885ARG1 231/4885ARG2 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.